At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Urinary biomarkers may have the potential to detect early treatment responses or failures in patients with lupus nephritis, according to Andrea Fava, MD. He and other experts discussed the latest research into lupus nephritis and how apply the recent ACR guideline to refractory cases.
Dr. Langford’s final column reflects on 2025’s advocacy, challenges & member teamwork. Click through to read the outgoing ACR president’s parting thoughts.
Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.
The winning case study in this year’s Thieves Market highlight a case study from Malaysia with a patient who initially presented with seronegative inflammatory arthritis but experienced recurrent infections and had a porcelain aorta.
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
Richard F. Loeser, Jr., MD, MACR, delivering the Oscar Gluck Memorial Lecture at ACR Convergence 2025, discussed research into new treatments for osteoarthritis.